News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
H.C. Wainwright has reiterated a buy rating and $7.00 price target for Tscan Therapeutics (NASDAQ: TCRX) following positive initial data from its Phase 1 ALLOHA-1 study for blood cancers. The study showed significant patient response rates and successful manufacturing, with a Phase 3 study …
TScan Therapeutics (NASDAQ:TCRX) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $6.00. The company's shares are trading near their 52-week low, and its recent quarterly results showed a mixed performance with an earnings beat but a …
TScan Therapeutics (TCRX) reported a narrower net loss of $30.4M, or $0.23 per share, for Q2 2026, an improvement from the $0.28 per share loss in Q2 2025. Revenue, however, declined significantly to $1.1M from $3.1M in the prior year. Despite revenue fluctuations typical …
This article provides a comprehensive overview of TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. It includes current stock price, historical performance data, key financial metrics, analyst ratings, and a company profile detailing its …
TScan Therapeutics, Inc. (TCRX) reported its Q2 2026 financial results, with revenue of $1.05 million and a net loss of $30.36 million, resulting in a diluted EPS of $(0.23). While revenue declined year-over-year, both net loss and EPS showed improvement. The company also announced …
TScan Therapeutics announced its second-quarter 2026 results, reporting $1.1 million in collaboration revenue and a net loss of $30.4 million. The company ended the quarter with $100.2 million in cash and cash equivalents, which are expected to fund operations into Q2 2027. Operationally, TScan …
TScan Therapeutics reported a narrowed net loss of $30.4 million in Q2 2026, down from $37.0 million in Q2 2025, primarily due to reduced R&D and G&A expenses despite a revenue decline. The company also announced significant clinical progress, dosing the first patient in …
This article reports that Tscan Therapeutics Inc. filed a Form 8K on August 12. The brief announcement provides no further details but links to the company's stock symbol TCRX. The article is part of Investing.com's financial news coverage.
TScan Therapeutics, Inc. (TCRX) reported a Q2 loss of $0.23 per share, exceeding the Zacks Consensus Estimate of a $0.29 loss, marking an earnings surprise of 20.69%. However, the company missed revenue estimates, posting $1.05 million against an expected $2.75 million, and its shares …
This article provides current stock news for TScan Therapeutics Inc (TCRX) from TradingKey. It highlights the company's stock performance, market capitalization, and indicates that more news and updates will be posted soon. The page serves as a hub for financial information regarding TCRX.
TScan Therapeutics Inc (TCRX) is projected to report a loss of 21 cents per share. This information comes from a Reuters earnings preview. The full article content is available on TradingView, which provides access to Reuters news.
TScan Therapeutics Inc (TCRX) has an earnings forecast score of 7.71 and an average price target of $6.00, with a high of $12.00 and a low of $4.00, based on 7 analysts. The company's expected revenue for the next quarter is $1.67 million, and …
This article provides a comprehensive stock analysis of TScan Therapeutics Inc (TCRX) by TradingKey. It highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The analysis also points out high institutional ownership, recent "Buy" …
LifeSci Capital has reiterated its Buy rating on TScan Therapeutics (TCRX.US) and maintained its target price at $6. This indicates continued confidence from the firm in the company's prospects.
TScan Therapeutics has dosed the first patient in its pivotal Phase 3 ALLOHA-2™ trial for TSC-101, a T-cell therapy aimed at preventing relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplantation. The trial is actively enrolling …
TScan Therapeutics Inc. has dosed the first patient in its phase 3 ALLOHA-2 trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial is evaluating TSC-101 to prevent relapse after stem cell transplantation, with topline data expected in mid-2028. TSC-101 is TScan's …
TScan Therapeutics announced the dosing of the first patient in its pivotal Phase 3 ALLOHA-2™ trial for TSC-101. This study evaluates TSC-101 for preventing relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplantation. The company expects …
This article provides a technical analysis of TScan Therapeutics Inc (TCRX), focusing on its stock price momentum, support and resistance levels, and key technical indicators. The stock is currently trading between a resistance level of $1.13 and a support level of $0.58, suggesting suitability …
Short interest in TScan Therapeutics (NASDAQ:TCRX) nearly doubled in July, increasing by 95.5% to 1.38 million shares, representing approximately 2.3% of the company's stock. The stock opened at $0.74, near its 12-month low, as the company continues to report significant losses and weak revenue. …
This article provides a detailed quarterly and annual income statement for TScan Therapeutics Inc (TCRX), including financial figures for total revenue, operating expenses, R&D expenses, operating profit, and net income stretching back to 2020. It also includes frequently asked questions about interpreting income statements …
This article provides TScan Therapeutics Inc (TCRX) cash flow statements, including operating, investing, and financing cash flows presented quarterly and annually. It includes detailed financial data and definitions for each type of cash flow, allowing users to assess the company's financial health. The data …
This article provides an overview of TScan Therapeutics Inc (TCRX) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page displays nil data for historical dividend records, suggesting TCRX …
This article provides an overview of TScan Therapeutics Inc. (TCRX) stock, including real-time quotes, market trends, key financials, and analyst ratings. Despite a recent weak stock market performance, the company shows strong fundamentals and is considered to have significant growth potential, although its stock …
This article provides a valuation analysis for TScan Therapeutics Inc (TCRX), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.34, placing it 148th in the Biotechnology & Medical Research industry. It also notes that relevant data for P/B, P/S, …
TScan Therapeutics Inc. (TCRX) is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer patients. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies, while it also has multiple TCR-T therapy programs for solid tumors. …
TScan Therapeutics, Inc. (TCRX) announced a Q1 loss, missing revenue estimates. This indicates a challenging start to the fiscal year for the company, with financial performance not meeting analyst expectations.
Search by ticker symbol or company name and select a result to open its chart.